ArticleLancet (London, England)2011
Vaccine discovery and translation of new vaccine technology.
Article in Lancet (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Fluorinated carbohydrate-based vaccines.Chemical science · 2026Review
- Article
- Oral and parenteral vaccination of broiler chickens with Recombinant NetB antigen from Clostridium perfringens confers significant protection against necrotic enteritis.BMC veterinary research · 2025Article
- A Comprehensive Review of Our Understanding and Challenges of Viral Vaccines against Swine Pathogens.Viruses · 2024Review
- Design of a novel multiepitope vaccine against Chlamydia pneumoniae using the extracellular protein as a target.Scientific reports · 2023Article
- A Hitchhiker's Guide to Problem Selection in Carbohydrate Synthesis.ACS central science · 2023Review
- Evaluation the efficacy of oral immunization of broiler chickens with a recombinant Lactobacillus casei vaccine vector expressing the Carboxy-terminal fragment of α-toxin from Clostridium perfringens.BMC veterinary research · 2023Article
- Lactobacillus casei displaying Clostridium perfringens NetB antigen protects chickens against necrotic enteritis.Applied microbiology and biotechnology · 2022Article
- Recent developments in systems biology and genetic engineering toward design of vaccines for TB.Critical reviews in biotechnology · 2022Review
- The Role of General Attitudes and Perceptions Towards Vaccination on the Newly-Developed Vaccine: Results From a Survey on COVID-19 Vaccine Acceptance in China.Frontiers in psychology · 2022Article
- Computational Design of a Multi-Epitope Vaccine AgainstFrontiers in immunology · 2022Article
- Vaccine and vaccination as a part of human life: In view of COVID-19.Biotechnology journal · 2022Review
- Semi- and fully synthetic carbohydrate vaccines against pathogenic bacteria: recent developments.Biochemical Society transactions · 2021Review
- Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach.Chemical reviews · 2021Review
- Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Beyond COVID-19 Vaccination: Global Human Unity and Ensuing Economic Alliances.Frontiers in public health · 2021Article
- Application of antigen presenting cell-targeted nanovaccine delivery system in rhabdovirus disease prophylactics using fish as a model organism.Journal of nanobiotechnology · 2020Article
- Bacterial vaccines in poultry.Bulletin of the National Research Centre · 2020Review
- Vaccine confidence in China after the Changsheng vaccine incident: a cross-sectional study.BMC public health · 2019Article
- Personalized vaccinology: A review.Vaccine · 2018Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An unprecedented increase in new vaccine development has occurred over the past three decades. This activity has resulted in vaccines that protect against an increased range of vaccine-preventable diseases, vaccines that reduce the number of required injections, and vaccines with improved safety and purity. New methods of discovery, such as reverse vaccinology, structural biology, and systems biology, promise new vaccines for different diseases and efficient development pathways for these vaccines. We expect development of vaccines not only for infectious diseases in children but also for healthy adults, pregnant women, and elderly people, and for new indications such as autoimmune disease and cancer. We have witnessed a concomitant development of new technology for assessment of vaccine safety to rapidly identify potential safety issues. Success of these new approaches will depend on effective implementation of vaccination programmes, creative thinking on the part of manufacturers and regulators as to how best to ensure that safe and effective vaccines are available in a timely manner, and improvement of public awareness about the benefits and risks of new vaccines in a way that encourages confidence in vaccines.
Indexed as
Identifiers
21664687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.